Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma

Investigation to Evaluate the Levels of Human Germinal-center-Associated Lymphoma (HGAL) Protein in Pediatric Hodgkin Lymphoma and Correlate With Early Response

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01366157

Enrollment

Registered

2011-06-03

Start date

2011-05-31

Completion date

2016-05-31

Last updated

2016-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

childhood favorable prognosis Hodgkin lymphoma, stage I childhood Hodgkin lymphoma, stage II childhood Hodgkin lymphoma, stage III childhood Hodgkin lymphoma, stage IV childhood Hodgkin lymphoma, childhood lymphocyte depletion Hodgkin lymphoma, childhood lymphocyte predominant Hodgkin lymphoma, childhood mixed cellularity Hodgkin lymphoma, childhood nodular lymphocyte predominant Hodgkin lymphoma, childhood nodular sclerosis Hodgkin lymphoma

Brief summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research trial is studying protein biomarker levels in tissue samples from young patients with low-risk Hodgkin lymphoma.

Detailed description

OBJECTIVES: * To investigate the variability of expression of human geminal-center-associated lymphoma (HGAL) protein in pediatric low-risk Hodgkin lymphoma. * To assess the variability of HGAL staining between risk groups by comparing samples from subjects enrolled in the low-risk study AHOD0431 with subject samples enrolled in AHOD0031 for intermediate-risk classical Hodgkin Lymphoma (cHL). * To assess the variability of HGAL staining by evaluating a tissue array created from subjects with intermediate-risk cHL. * To correlate rapid or slow early-response in the intermediate-risk group with HGAL protein expression. OUTLINE: Paraffin-embedded tissue samples and tissue microarrays are analyzed for protein expression by IHC.

Interventions

GENETICmicroarray analysis

GENETICprotein expression analysis

OTHERimmunohistochemistry staining method

OTHERlaboratory biomarker analysis

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 21 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosed with low-risk classical Hodgkin lymphoma (cHL) * Samples available from patients enrolled in the low-risk study COG-AHOD0431 and in the intermediate-risk cHL study COG-AHOD0031 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Variability of HGAL protein expression in pediatric patients with low-risk classical Hodgkin lymphoma (cHL)	—
Variability of HGAL staining between low-risk and intermediate-risk pediatric patients with cHL	—
Variability of HGAL staining as assessed by tissue array in pediatric patients with intermediate-risk cHL	—
Correlation of rapid or slow early response in the intermediate-risk group with HGAL protein expression	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026